Immunoassay Tests

To support the use of the QLCA, we are developing several immunoassay tests designed to enhance the management of patients with cardiovascular diseases.






Troponin I (TNI) Test

  • TnI testing is the current routine testing for a heart attack.
  • TnI is a heart muscle protein, released in the bloodstream shortly after a heart attack (myocardial infarction or MI).
  • Current laboratory analyzers cannot detect TnI before 4-6 hours after the onset of symptoms, when TnI concentration in the blood reaches its detection threshold.
  • Physicians to obtain much more rapid results and therefore accelerate patient triage.
  • Our test will take only 15 minutes to deliver quantitative results, allowing better patients' management

Plasminogen Activator Inhibitor Type-1 (PAI-1) Test

  • This test will help to optimize the performance of a heart drug, (tPA, tissue plasminogen activator) a clot buster used as the first line of therapy for MI patients.
  • Forty percent of patients do not respond to tPA, a fact recognized only after the “golden hour” (the time period in which permanent heart damage can be prevented) has passed.
  • This proprietary whole blood test will quantify PAI-1 levels within 15 minutes.

Heart Failure Risk Stratification (HFRS)

  • With the aging population and better outcome of acute coronary events, heart failure is becoming an epidemic with an increasing number of people suffering from this disease nicknamed, “the malignant disease of the heart”.
  • Currently, biochemical markers are a cornerstone in the management of patients with heart failure.
  • Brain Natriuretic peptides are the most commonly employed markers for diagnosis and risk-stratifying patients with heart failure.
  • Natriuretic peptides are very poor in identifying heart failure in diastolic failures, a common form of heart failure in elderly female patients, where the threshold of significance is very controversial.
  • We are developing a proprietary test, the Heart Failure Risk Stratification or HFRS test to stratify the risk of death in patients with heart failure, thus permitting the initiation of appropriate therapy at an early stage.

Heart Failure Genomics Risk (HFGR)

  • We are developing a proprietary HFGR test that predicts the response of heart failure patients to routinely administered drugs.
  • The need to measure the precise response to these drugs in a timely manner would minimize the trial and error methods now used by doctors to optimize drugs best suited to each patient.

Stock Info

Information for stock quote is provided 'as is' and solely for informational purposes, not for trading purposes or advice, and may be delayed.